{"ticker": {"uuid": "45ae2535-5faa-4a44-8e2e-70c13ea25772", "symbol": "ENLV", "name": "Enlivex Therapeutics Ltd", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Enlivex Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Allocetra\u2122 in Age-Related Knee Osteoarthritis", "summary": "Enlivex Ltd. has received FDA Regenerative Medicine Advanced Therapy (RMAT) designation for its immunotherapy Allocetra\u2122 to treat age-related knee osteoarthritis in patients aged 64 and older. This designation, based on positive Phase I/IIa trial data, streamlines the development", "url": "https://www.manilatimes.net/2026/07/13/tmt-newswire/globenewswire/enlivex-receives-fda-regenerative-medicine-advanced-therapy-rmat-designation-for-allocetra-in-age-related-knee-osteoarthritis/2383297", "source_name": "The Manila Times", "published_at": "2026-07-14T04:11:31", "published_display": "14 Jul 2026 04:11", "sentiment": "positive", "sentiment_pct": 91, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enlivex (ENLV) Receives RMAT Designation for Knee Osteoarthritis Treatment", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxPQkdiLWNabDUwZlFydWFlZVZQN1J6WlRjMmxseC05NXFETlFlNTRpV1lITVFCQXRrTWNGVjFrakc3ZlVJdUVPZk8wNXppekxqdXRFQUhQWmtmZUtFNUM3RkdrRDZlNlFIcXlsNEJOdVZ6eEFwT3hZVU1nR29fbTRqQWhKS0dQUmp1ZTMwZ2luMktQMDZCRkhWUGlmc0trQ3FuNFB6TnpZa2dCNGkwam1jT2xuU3REWTNwdlRXWDU0RVc?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-13T19:45:01+00:00", "published_display": "13 Jul 2026 19:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enlivex Ltd. (ENLV) Upgraded to Buy: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxQMVg0T2diOW9sNmpJeDhmMWZNUGYyOGtNNllrN090M2xSelEtY09CTFJCQ2NTR1VpT05ySUVVSnRfc0l0SHlkWjJfc0lPM3B2TXpfYWp4VzRENDYtaWlTWDRWZXFYdWNEbi1JR0JRbl92Q2tfTWRiemI5Tjd3ZFVqZWt2cmp6dzVPTWNPdi1weTZfaHZwbEJrWlZR?oc=5", "source_name": "Market source", "published_at": "2026-07-13T16:00:03+00:00", "published_display": "13 Jul 2026 16:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enlivex Ltd. (ENLV) Loses 31.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner", "summary": "Enlivex Ltd. (ENLV) has recently experienced a 31.7% loss in share value over four weeks, placing it in oversold territory according to its Relative Strength Index (RSI) of 19.3. This technical indicator, combined with rising earnings estimates from Wall Street analysts and a Zac", "url": "https://finance.yahoo.com/markets/stocks/articles/enlivex-ltd-enlv-loses-31-133502878.html", "source_name": "Market source", "published_at": "2026-07-13T13:35:00", "published_display": "13 Jul 2026 13:35", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enlivex's Allocetra Receives FDA RMAT Designation for Knee Osteoarthritis", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/enlivex-apos-allocetra-receives-fda-123313590.html", "source_name": "MT Newswires", "published_at": "2026-07-13T12:33:13+00:00", "published_display": "13 Jul 2026 12:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Enlivex (ENLV) wins FDA RMAT designation for Allocetra in age-related knee osteoarthritis", "summary": "Enlivex Ltd. announced that the FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to its immunotherapy drug, Allocetra\u2122, for treating age-related symptomatic knee osteoarthritis in patients 64 and older. This designation, based on positive Phase I/IIa tria", "url": "https://www.stocktitan.net/sec-filings/ENLV/6-k-enlivex-ltd-current-report-foreign-issuer-61adaba508fd.html", "source_name": "Stock Titan", "published_at": "2026-07-13T11:40:58", "published_display": "13 Jul 2026 11:40", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA flags Enlivex\u2019s Allocetra as potential new option for painful knee osteoarthritis", "summary": "The FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to Enlivex's Allocetra for age-related knee osteoarthritis in patients 64 and older, aiming to accelerate its development. This designation was based on positive Phase I/IIa trial data showing significa", "url": "https://www.stocktitan.net/news/ENLV/enlivex-receives-fda-regenerative-medicine-advanced-therapy-rmat-8tzm8f2vmzb5.html", "source_name": "Stock Titan", "published_at": "2026-07-13T11:40:58", "published_display": "13 Jul 2026 11:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exclusive: FDA grants RMAT designation to Enlivex\u2019s Allocetra for knee OA", "summary": "The FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to Enlivex's experimental immunotherapy Allocetra for age-related knee osteoarthritis in patients aged 64 and older. This designation is expected to provide the biotech company with enhanced access to t", "url": "https://ca.investing.com/news/stock-market-news/exclusive-fda-grants-rmat-designation-to-enlivexs-allocetra-for-knee-oa-4730690", "source_name": "Investing.com Canada", "published_at": "2026-07-13T10:40:58", "published_display": "13 Jul 2026 10:40", "sentiment": "positive", "sentiment_pct": 95, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tranche Update on Enlivex Therapeutics Ltd.'s Equity Buyback Plan announced on September 18, 2023.", "summary": "", "url": "https://news.google.com/rss/articles/CBMi_wFBVV95cUxOd2hRX0ZNUklMX2xTOWJDajBOeE1XRE9WcklsbTZGRFV3YWpmVnVWcHp2UFFJaEt4Qkp0QzNuQ0FyN3FfUXVmcmxGNDJWVS01NEE1Y2xiTzEtYl8xNHBZRThlREhLY2RrdVFhYTJ0Qng3VW5wWHA4Tk10NkdZWkt5SXI0MHVUeERZM25QR3hUc2FZMkEwWm1YTTNMSWpyVDMxUjlKZG1DcVBkSTBFWlFiQTBqWHFTS3BtZGpfRE5aVmlDdFk3THp4UUJDUDh6dmJBbzRvMklXWU8yd1gzc1VRdzgtX3JQdnFFVnF1UVFnY0RweFBvdEIyVEdpX1JVcXM?oc=5", "source_name": "marketscreener.com", "published_at": "2026-07-12T15:57:57+00:00", "published_display": "12 Jul 2026 15:57", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enlivex: Shareholders Board Members Managers and Company Profile | IL0011319527", "summary": "This article provides a comprehensive company profile for Enlivex Ltd. (IL0011319527), an Israel-based clinical-stage macrophage reprogramming immunotherapy company. It details the company's business description, key executives, board members, major shareholders, and financial ov", "url": "https://www.marketscreener.com/quote/stock/ENLIVEX-56422776/company/", "source_name": "www.marketscreener.com", "published_at": "2026-07-11T03:39:41", "published_display": "11 Jul 2026 03:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enlivex Sets 1-for-15 Reverse Stock Split Ahead of July 9 Nasdaq Debut", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7gFBVV95cUxOZUVPMmFMTWV3MUV3RFZvem5fYWxNOVdUNkZDbE94Y0prS3A5V3V1ekNOZ3FXU3N3SG9kUEFkRERIOGpldUhqN1JjVnJRNjVtLTlyZEktVWpOU25sRmFRTVZlZXhNVTdCQTJybWNfaFdzNVJ1MXVZUjNKMTAyZFYyUHB1Vl9VdEFENWdQeTUwM0lySGRNU1BkaktmdEx2ckJrYUpXRk9KMGlDV1dmY2dsQkZxeDNvT014enF1NHdNRGY5bVFPYXFwMDBfcTFRQnNyTXVvZUJoNnFFaEJqeFRRUHdUWVpjQ1g2SVluaW9R?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-07-08T07:00:00+00:00", "published_display": "08 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enlivex Announces 1-for-15 Reverse Stock Split Effective July 9, 2026", "summary": "Enlivex Ltd. announced a 1-for-15 reverse stock split of its ordinary shares, effective July 9, 2026. This action will combine every fifteen ordinary shares into one, reducing the total number of outstanding shares and proportionately adjusting par value, exercise prices, and the", "url": "https://www.manilatimes.net/2026/07/07/tmt-newswire/globenewswire/enlivex-announces-1-for-15-reverse-stock-split-effective-july-9-2026/2379846/amp", "source_name": "The Manila Times", "published_at": "2026-07-07T14:12:17", "published_display": "07 Jul 2026 14:12", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enlivex announces 1-for-15 reverse stock split effective Wednesday By Investing.com", "summary": "Enlivex Ltd. announced a 1-for-15 reverse stock split of its ordinary shares, effective Wednesday, July 9, 2026, to address its stock trading near a 52-week low. This adjustment will reduce the number of authorized shares and outstanding ordinary shares, but will not affect share", "url": "https://ng.investing.com/news/stock-market-news/enlivex-announces-1for15-reverse-stock-split-effective-wednesday-93CH-2588871", "source_name": "Investing.com Nigeria", "published_at": "2026-07-07T14:12:16", "published_display": "07 Jul 2026 14:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enlivex Therapeutics outlines its immunotherapy approach as a clinical-stage biotech", "summary": "Enlivex Therapeutics is a clinical-stage biotechnology company focused on developing immunotherapy candidates for severe inflammatory conditions and oncology, with shares traded on Nasdaq. The company's strategy involves modulating immune cell behavior to address unmet medical ne", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/enlivex-therapeutics-outlines-its-immunotherapy-approach-as-a/69714766", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T13:52:07", "published_display": "07 Jul 2026 13:52", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enlivex (ENLV) Implements Reverse Stock Split", "summary": "Enlivex Ltd (ENLV) announced a 1-for-15 reverse stock split effective July 9, 2026, a strategic move to increase its share price and comply with Nasdaq listing requirements. The biotechnology company, focused on developing Allocetra for osteoarthritis, has a P/E ratio of 0.1x, po", "url": "https://www.gurufocus.com/news/8947326/enlivex-enlv-implements-reverse-stock-split", "source_name": "GuruFocus", "published_at": "2026-07-07T13:42:07", "published_display": "07 Jul 2026 13:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enlivex to shrink share count 15-to-1 on July 9 as Nasdaq trading continues", "summary": "Enlivex (Nasdaq: ENLV) announced a 1-for-15 reverse stock split of its ordinary shares, effective July 9, 2026, to maintain Nasdaq listing compliance. This action will reduce the number of outstanding shares from 252,480,222 to approximately 16,832,015 and increase the par value ", "url": "https://www.stocktitan.net/news/ENLV/enlivex-announces-1-for-15-reverse-stock-split-effective-july-9-rfk94ihhvnlh.html", "source_name": "Stock Titan", "published_at": "2026-07-07T12:12:08", "published_display": "07 Jul 2026 12:12", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enlivex (Nasdaq: ENLV) enacts 1-for-15 reverse split and cuts share count", "summary": "Enlivex Ltd. (Nasdaq: ENLV) announced a 1-for-15 reverse stock split, effective July 9, 2026, to consolidate its ordinary shares. This action will reduce authorized shares from 2.375 billion to approximately 158.3 million and outstanding shares from 252.48 million to about 16.83 ", "url": "https://www.stocktitan.net/sec-filings/ENLV/6-k-enlivex-ltd-current-report-foreign-issuer-48a517248570.html", "source_name": "Stock Titan", "published_at": "2026-07-07T12:12:07", "published_display": "07 Jul 2026 12:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enlivex (NASDAQ: ENLV) highlights RAIN listing on Gate and $1.14B treasury", "summary": "Enlivex Ltd. (NASDAQ: ENLV) announced that its primary treasury asset, the RAIN token, is expected to be listed on the Gate cryptocurrency exchange on June 24, 2026, at 10:00 AM UTC. This listing aims to increase RAIN's accessibility, global reach, and liquidity, supporting Enliv", "url": "https://www.stocktitan.net/sec-filings/ENLV/6-k-enlivex-ltd-current-report-foreign-issuer-cf58f98a14ad.html", "source_name": "Stock Titan", "published_at": "2026-06-24T12:12:02", "published_display": "24 Jun 2026 12:12", "sentiment": "positive", "sentiment_pct": 64, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enlivex token gets Gate listing, widening access to its $1.14B treasury asset", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxOdHJtNHNHSDUtcTR5U2R4MUEtdEhEYTIzOXRYUDZPTEdWaXFQS2xDQzVRUHlFYmpuVGVQOVFpRm1LbmNBZlA5REVNVkZHVVU3NlJZSnRtOFowaG9CUlZfdzBpeEtKRkV6ZXpjUVozc25RX0V2Y1JWR056dm1TejdTSk9Ba29KcWNRM0hzWEZDNkxQNzFjVTJMdkI0YVNkU3lzR0YyZjJHMlUzNlZBbEZxSGlpT05VQXQ0bDQ3NDVHRQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enlivex Therapeutics Ltd (ENLV) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Enlivex Therapeutics Ltd (ENLV), detailing its current price momentum score, support and resistance levels, and insights from various technical indicators and moving averages. The analysis suggests that the stock is currently trading ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-enlv/technical", "source_name": "TradingKey", "published_at": "2026-06-23T11:10:14", "published_display": "23 Jun 2026 11:10", "sentiment": "negative", "sentiment_pct": 36, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 6K Enlivex Therapeutics Ltd For: 22 June By Investing.com", "summary": "This article reports on the filing of Form 6K by Enlivex Therapeutics Ltd for June 22nd. The filing is brief and includes the stock ticker ENLV, which experienced a slight decline. The page also features various financial market data and related news.", "url": "https://za.investing.com/news/stock-market-news/form-6k-enlivex-therapeutics-ltd-for-22-june-93CH-4337745", "source_name": "Investing.com South Africa", "published_at": "2026-06-23T08:10:26", "published_display": "23 Jun 2026 08:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enlivex Therapeutics Ltd (ENLV) Risk Assessment: Volatility, Financial Risk & Investment Risk", "summary": "This article provides a risk assessment for Enlivex Therapeutics Ltd (ENLV), noting that no specific risk assessment score is currently available, but the industry average is 3.36. It highlights the company's beta value of 1.67, indicating higher volatility compared to the S&P 50", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-enlv/risk-assesment", "source_name": "TradingKey", "published_at": "2026-06-23T05:40:54", "published_display": "23 Jun 2026 05:40", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enlivex Reports $1.14 Billion Value in RAIN Token Holdings as of June 20, 2026", "summary": "Enlivex Ltd. announced holdings of 79.5 billion RAIN tokens valued at $1.14 billion as of June 20, 2026, contributing to a Treasury NAV per Share of $4.67. The company employs a dual strategy, advancing its Allocetra\u2122 immunotherapy and managing a prediction markets treasury throu", "url": "https://www.quiverquant.com/news/Enlivex+Reports+%241.14+Billion+Value+in+RAIN+Token+Holdings+as+of+June+20%2C+2026", "source_name": "Quiver Quantitative", "published_at": "2026-06-22T12:50:00", "published_display": "22 Jun 2026 12:50", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[6-K] Enlivex Ltd. Current Report (Foreign Issuer) | ENLV SEC Filing - Form 6-K", "summary": "Enlivex Ltd. filed a Form 6-K report, updating on its digital asset treasury. As of June 20, 2026, the company held 79.57 billion RAIN tokens, valued at approximately $1.14 billion, leading to an unaudited Treasury NAV per Share of $4.67. Enlivex emphasizes its dual strategy of a", "url": "https://www.stocktitan.net/sec-filings/ENLV/6-k-enlivex-ltd-current-report-foreign-issuer-808f6becf666.html", "source_name": "Stock Titan", "published_at": "2026-06-22T12:39:44", "published_display": "22 Jun 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enlivex says its RAIN token treasury is worth about $1.14 billion", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQSm1mVDEtOUJVMWRXMGRQS25YT2FwTjdDaEowaFh1bUN1dWUtc094UnNVVVN6UXVIQWFaemtNYzV6UC1YWGVIR1JDVjdJSGFLLWQ4Wm94eHpmSzMtT3RQRmJ0eTdULVlGZkFCZ25SY2tFNWJjUkpRRmxnYU9wQ1k5YkdINzlENjNqNllMZGJFUVdKVkVfZEpITFNmNDRvaC10c2d0aTVJbzlIVmxMektqZUVB?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ENLV Stock - weekly outlook with no verified hook", "summary": "This article provides a weekly outlook for Enlivex Therapeutics (ENLV) stock, noting the absence of a live-verifiable corporate hook in recent search results. It focuses on the company's clinical-stage profile as a macrophage reprogramming immunotherapy business and highlights th", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/enlv-stock-weekly-outlook-with-no-verified-hook/69591420", "source_name": "AD HOC NEWS", "published_at": "2026-06-20T15:40:30", "published_display": "20 Jun 2026 15:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enlivex Therapeutics Ltd (ENLV) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Enlivex Therapeutics Ltd (ENLV) has an earnings forecast score of 8.00, placing it well within its industry. Analysts predict a price target of $7.00, with a consensus \"Buy\" rating based on one analyst's assessment. The company's previous EPS was -$0.09, with the next quarter's E", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-enlv/earnings", "source_name": "TradingKey", "published_at": "2026-06-19T02:19:54", "published_display": "19 Jun 2026 02:19", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enlivex Therapeutics Ltd (ENLV) Financial Health: Profitability & Balance Sheet Analysis", "summary": "This article provides an analysis of Enlivex Therapeutics Ltd's (ENLV) financial health, highlighting its weak financial status and low operating efficiency within the Biotechnology & Medical Research industry. The company's financial score is 5.38, ranking it poorly compared to ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-enlv/financial-health", "source_name": "TradingKey", "published_at": "2026-06-18T23:10:18", "published_display": "18 Jun 2026 23:10", "sentiment": "negative", "sentiment_pct": 31, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enlivex Therapeutics Ltd (ENLV) Institutional Confidence", "summary": "This article provides an \"Institutional Confidence\" overview for Enlivex Therapeutics Ltd (ENLV), indicating a score of 3.00, unchanged from the previous score as of June 18, 2026. It highlights institutional shareholding data, specifically mentioning Shai A. Novik's stake of 858", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-enlv/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T06:19:54", "published_display": "18 Jun 2026 06:19", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enlivex Therapeutics Ltd (ENLV) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article from TradingKey provides an overview of Enlivex Therapeutics Ltd (ENLV), focusing on its revenue breakdown. However, it indicates that relevant data regarding business segments, regional revenue, and profit contribution for ENLV have not yet been disclosed by the com", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-enlv/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T21:40:25", "published_display": "17 Jun 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enlivex Therapeutics Ltd (ENLV) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Enlivex Therapeutics Ltd (ENLV) stock information, focusing on its dividend and stock split history. It indicates that the company has not distributed any dividends in the past five years and has no record of stock splits. The page also displa", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-enlv/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T21:40:25", "published_display": "17 Jun 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enlivex Therapeutics Ltd (ENLV) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of Enlivex Therapeutics Ltd (ENLV), listing major shareholders such as Gems Foundation, Token Factory, and Sobrinia Ltd, along with their respective proportions. It also presents a breakdown of shareholder types, indicating that corp", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-enlv/ownership", "source_name": "TradingKey", "published_at": "2026-06-17T20:40:25", "published_display": "17 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enlivex receives Australian patent for osteoarthritis treatment", "summary": "Enlivex Ltd. has been granted an Australian patent for its Allocetra therapy to treat osteoarthritis, providing intellectual property protection in Australia through at least 2040. This news comes as the company's shares trade near their 52-week low, and they are currently conduc", "url": "https://au.investing.com/news/stock-market-news/enlivex-receives-australian-patent-for-osteoarthritis-treatment-93CH-4487321", "source_name": "Investing.com Australia", "published_at": "2026-06-16T06:39:19", "published_display": "16 Jun 2026 06:39", "sentiment": "positive", "sentiment_pct": 69, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enlivex receives Australian patent for osteoarthritis treatment By Investing.com", "summary": "Enlivex Ltd. has been granted an Australian patent for its Allocetra therapy for osteoarthritis, extending intellectual property protection until at least 2040. This news comes as the company's shares trade near a 52-week low, despite positive clinical trial data for Allocetra in", "url": "https://uk.investing.com/news/stock-market-news/enlivex-receives-australian-patent-for-osteoarthritis-treatment-93CH-4728114", "source_name": "Investing.com UK", "published_at": "2026-06-15T17:39:25", "published_display": "15 Jun 2026 17:39", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enlivex Therapeutics Granted Patent in Australia for Allocetra to Treat Osteoarthritis", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/enlivex-therapeutics-granted-patent-australia-133827958.html", "source_name": "MT Newswires", "published_at": "2026-06-15T13:38:27+00:00", "published_display": "15 Jun 2026 13:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Australian patent backs Enlivex cell therapy for knee osteoarthritis to 2040", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQRnZhZ2RIdDN3N3VPUHhSYVpTWW0tTkJ6QzY1b25DX0VYNXJFZ25Ra25FNk55LU5fX1dkaHBWaWoyaEx2QVphbFIzWm02Q0ZtMC03SWFDNFFqeHgxZkhVcENYOFZlejl1TmxLU1RFODF3R3ZWQ2dSMFhwNmxJLXVkcjFHaEpza3ROZ0Zuemp5RjBRdWgtdFMzZjFSOEdibzlNNlBvTWg0ZHktN1NCNXNkZE5VVHZ6MlhzR1dHMGdGTQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enlivex Therapeutics stock (IL0011283620): Data monitoring, Nasdaq notice and next steps for investo", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxNaWlhdFNRRktUYWpmdDh0N0YwSUxsQ3BHQ1JoTElybFV5VkZwUWEzaE9hVFA1b0F0T2hvM2tGUnVybk1LbmRlVzQ3enFIbThreEpSYk1ScEppM3F0bUZJc3JDMnNqMXRHWVhDazFzWVRLVVhlU1l2czlmdHZlVWotYm1PN2JITXM1ZHVCTktKY3NsX285UUxDdW1ielZqOUstMjFsX2lZRUN6Y29EUlUtQl9uLWgtcEltZXE4OFBiSV9lQldISzJV?oc=5", "source_name": "ad-hoc-news.de", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enlivex brings longevity\u2011prediction markets pitch to $18T Paris summit", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxNR0kzcEs0TWcybndNUmtmajFvMVd6MkJlbVY2b3hBQUo0N0oxb2pyUVFpNVplYVNhaG9nR3FGMkpFZ0g1bGU1WVNiZWlNZFlocERRaHI2VU1OTlJIakc1b29PWV91aUZTMlhEcXkwTkFTTFZSSnVzdThvN0M3OVh6SXFMSUt1NFo0V2oxenQ2NldQRFFtN2lycno4Wldvdm0xZnpURWdmM2ExaVd4MkpMTkFuLW5UZ2ZzMmZB?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQcjZqdzdBcURDdWxCZUtoU1dTaHYtVUFRdlo1a3ZGZGY3a1dBX2x2UVE3Y1hoX1duLXhGU2p0UXU2eTctNng5eFJ5c1M0bHBNQ0VmZTFZanhYU21yTVo0UTQtVENveVV1aWdpc3luUlgza3AyUEI2OGx4aEhXc0pBTHpWUThSYXI1S3RTS21lQ21vWjd6MGY4ZDRwVWlEakc3SmFKN09aM0Rlb2pFT3BNNW1GTExnSElFb2NqR3JhX0J3MlptQy1mMk9IOTZtdS1HU25fLU9aOU9XZi1PRDlkZVI2cnhackHSAewBQVVfeXFMTlc2N3pIUkxDd1NtTlVRMEdac1JNSDF3cUNidkZrTElQREZaUTZjZmFHdUVWYW8wcDg1LThGbnlPb0VQUFI4ZXdjSXR6Ym5DREM1X2lyQUtYTzF3XzBBTGRGcEZQQ3FjLWxCQ0locVM2dGZJR1kxYmlBQXdsbFhfbFFISS1wSUkxQmp4U2d2Z3JHbXRPMUpnajBydTRmNnQzZmF5eEdzOVFRNUdDNVV0aDJQNERCaXN3ZGo1UUc1ZGkwOFYzcDgxS1ltZllDeTFxNFIxT3FyOUxLMFNrLUhtOFNFV0xMYkM5TlpWMzk?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Enlivex advances Allocetra while expanding into prediction markets", "summary": "", "url": "https://finance.yahoo.com/video/enlivex-advances-allocetra-while-expanding-173935308.html", "source_name": "Proactive", "published_at": "2026-05-11T17:39:35+00:00", "published_display": "11 May 2026 17:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Enlivex to Present Phase IIa 3-month and 6-month Data of Allocetra at OARSI 2026 World Congress", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/enlivex-present-phase-iia-3-123000346.html", "source_name": "GlobeNewswire", "published_at": "2026-04-23T12:30:00+00:00", "published_display": "23 Apr 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "New knee osteoarthritis data from Enlivex heads to OARSI 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxOamw5aldETWpMOVVDN05TZkE3bHFkREJVd3RWLVctR0tIYlNqeHlYZTZUV1VXaDNWQ19GanhXYUQzc0dBXzZtSDVfZ2FZOWcwZHJUOW8tWTAxVTdkNGpzdDlMcFBxU1NDRW9ZSUJFMDN0MzdYZFl6NXg2VzJzX3NkYV9qSDY1czlfVXZDZWszN09qakM5R1hWZFkzQWxrcmtaUG1RR2VUcFVkbGUtaGw1cFM2MlNCaDdCUldldkF3aw?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-23T07:00:00+00:00", "published_display": "23 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "H.C. Wainwright Highlight Improved Balance Sheet Supporting Enlivex Ltd. (ENLV) Outlook", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxQajhpWE9vUFFRVGcyQUQwOGdrU0ZzUFFzNFpYSFFZTmdGR1U2c1lIQU93MF92STlYZExGdDBLWFVReERlV21BTWpkVlg0Ymd6Q1NTajlGSUpBQnpnVGJfUDlYczVLUnl2aF9CZTBJRzd4Zkg3Vk9KWXQ3WHBXWjFBVU51dV8ycHVSUjV4WHgxWE8zVjNoMmxaZGNEN2RPVHQ2Q3pOWQ?oc=5", "source_name": "Market source", "published_at": "2026-04-20T07:00:00+00:00", "published_display": "20 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Enlivex Ltd. Reports $1.23 Billion Net Income for 2025 Driven by Treasury Asset Appreciation | ENLV Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxPeGJTWmJhQXptdDhuLV84V1g0QmZuckJxREgwQ0RXR1V5X2pxMDBsQUF4bDV2dTJxaXdfeW4yR1BsdEd3WnljTi1QWGpLSTlnRWljMldmVnE2REJEN0ZSVVVoSVVvcDQ5R0NjN25IWXd5dTdDSUNJUDFPVF9JRWF1RVJBNGhLcmRjU3N0R0tlWDVUWUI4ZldJZnhqNWctNV9VUHJzUFltMXp2VC1NVURXYkJuNkhHMlVLaEhJc1B1U0RheXNOOXc?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Backed by $21M debt, Enlivex buys 3B more RAIN tokens at discount", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxPS1MydUlJQkllRDctV3p3NW1iTzZfOHl4RWNyNVY2dEdnekNldzJYMEFaRUc5MkxHMllCRHhvXy1qY1NIMVloWFJ6R1ZJMTJrUG9tSnNaa1BHNC1DN0N1ZTByS3V4ZllwZTBKX2ttNFh1dl9QTjFsekp0VFhMeFFiOEo4UG81LUlSMmk1TEx4T3F1MmNKVFU0Z1dXOEtFTmRhOW1VMzMwQ0M4a0R4NTI1dnRUd05aMmxFTmpJeDFBQWM?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-24T07:00:00+00:00", "published_display": "24 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enlivex Rebrands as Enlivex Ltd. Following Shareholder Approval", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2gFBVV95cUxQNEdkcHlRS3NPUXl6MlU1MFhsRE43MFRzZWpQTHc2eTRqUE9rZHNEQzBCWnNHWXI2cWdUWGlnanRZV0pJVkJOSXdQbkxLZWlxdm1MUlFlck5wOEZ6NHVMdFJHYmhaYTdPUkUxTUFXNUx5U20wek1RVnFPMjJwM2JYdlJ2ZGNLTGZNWFZDREhERDBYOVVqUVBWRUphQWRQVnEyTzU5NkRJSnhvTUJhdGIyOXdEN3Qzbm53VjRFZFVSZXB3WHl0U2ZKSmlOdHhOTkgzSV9MV2dPeDdmUQ?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enlivex Unveils $212M Rain Token DAT Strategy as RAIN Surges Over 120%", "summary": "", "url": "https://news.google.com/rss/articles/CBMigwFBVV95cUxOUmhHX0sxbEFSZ1ZHWlMxaGZ4Q0VOLXFINUM0Zm1qbFk5R0hvVEdFNXdVNkZNVFc5ZURtSXppVXR3V2dkY2d2dTlya3MtRDZaWktSS3R0ZkpPd2RVUHlZWTY2MF9VSEhsdlB4azFUaUE1Y2ZKYWRrcnFSdmFMYXpCSXJzYw?oc=5", "source_name": "Market source", "published_at": "2025-11-24T08:00:00+00:00", "published_display": "24 Nov 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EXCLUSIVE: Enlivex Raises Over $200 Million To Launch First Public Company Prediction Markets Play", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxOX0lnVUcwZzEwOVVQOFZzT3pxbzRiWXFXRUVqWlJRZjA2TDVKd19XTGtMNGVWOGJEWVVhREU3SGMzbzRoRWw2cFN6QzRCb3k1dkNBLWdaeU9rQzhfR3FaTnpRV2ZSa2lIbG01ZUhxaVJwUDRTSlp4bkdTdHF6LVFSNHNaSTB4dw?oc=5", "source_name": "Market source", "published_at": "2025-11-24T08:00:00+00:00", "published_display": "24 Nov 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why We're Watching Enlivex Therapeutics' (NASDAQ:ENLV) Cash Burn Situation", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-10-07T07:00:00+00:00", "published_display": "07 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enlivex Therapeutics (ENLV) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE5vNHo5VGxxS01hR0NtWExILUtLSHVUay1oaDZPQUxfTXI0by14b1BkNGxlUWV5U1lpbk1PTVhzcGtwZDltNjhuakI3d3ByZXkwbmtOQTdoS3QwUQ?oc=5", "source_name": "MarketBeat", "published_at": "2020-01-10T08:42:01+00:00", "published_display": "10 Jan 2020 08:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Enlivex Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Allocetra\u2122 in Age-Related Knee Osteoarthritis", "summary": "Enlivex Ltd. has received FDA Regenerative Medicine Advanced Therapy (RMAT) designation for its immunotherapy Allocetra\u2122 to treat age-related knee osteoarthritis in patients aged 64 and older. This designation, based on positive Phase I/IIa trial data, streamlines the development", "url": "https://www.manilatimes.net/2026/07/13/tmt-newswire/globenewswire/enlivex-receives-fda-regenerative-medicine-advanced-therapy-rmat-designation-for-allocetra-in-age-related-knee-osteoarthritis/2383297", "source_name": "The Manila Times", "published_at": "2026-07-14T04:11:31", "published_display": "14 Jul 2026 04:11", "sentiment": "positive", "sentiment_pct": 91, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enlivex (ENLV) Receives RMAT Designation for Knee Osteoarthritis Treatment", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxPQkdiLWNabDUwZlFydWFlZVZQN1J6WlRjMmxseC05NXFETlFlNTRpV1lITVFCQXRrTWNGVjFrakc3ZlVJdUVPZk8wNXppekxqdXRFQUhQWmtmZUtFNUM3RkdrRDZlNlFIcXlsNEJOdVZ6eEFwT3hZVU1nR29fbTRqQWhKS0dQUmp1ZTMwZ2luMktQMDZCRkhWUGlmc0trQ3FuNFB6TnpZa2dCNGkwam1jT2xuU3REWTNwdlRXWDU0RVc?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-13T19:45:01+00:00", "published_display": "13 Jul 2026 19:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enlivex Ltd. (ENLV) Upgraded to Buy: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxQMVg0T2diOW9sNmpJeDhmMWZNUGYyOGtNNllrN090M2xSelEtY09CTFJCQ2NTR1VpT05ySUVVSnRfc0l0SHlkWjJfc0lPM3B2TXpfYWp4VzRENDYtaWlTWDRWZXFYdWNEbi1JR0JRbl92Q2tfTWRiemI5Tjd3ZFVqZWt2cmp6dzVPTWNPdi1weTZfaHZwbEJrWlZR?oc=5", "source_name": "Market source", "published_at": "2026-07-13T16:00:03+00:00", "published_display": "13 Jul 2026 16:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enlivex Ltd. (ENLV) Loses 31.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner", "summary": "Enlivex Ltd. (ENLV) has recently experienced a 31.7% loss in share value over four weeks, placing it in oversold territory according to its Relative Strength Index (RSI) of 19.3. This technical indicator, combined with rising earnings estimates from Wall Street analysts and a Zac", "url": "https://finance.yahoo.com/markets/stocks/articles/enlivex-ltd-enlv-loses-31-133502878.html", "source_name": "Market source", "published_at": "2026-07-13T13:35:00", "published_display": "13 Jul 2026 13:35", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enlivex's Allocetra Receives FDA RMAT Designation for Knee Osteoarthritis", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/enlivex-apos-allocetra-receives-fda-123313590.html", "source_name": "MT Newswires", "published_at": "2026-07-13T12:33:13+00:00", "published_display": "13 Jul 2026 12:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enlivex (ENLV) wins FDA RMAT designation for Allocetra in age-related knee osteoarthritis", "summary": "Enlivex Ltd. announced that the FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to its immunotherapy drug, Allocetra\u2122, for treating age-related symptomatic knee osteoarthritis in patients 64 and older. This designation, based on positive Phase I/IIa tria", "url": "https://www.stocktitan.net/sec-filings/ENLV/6-k-enlivex-ltd-current-report-foreign-issuer-61adaba508fd.html", "source_name": "Stock Titan", "published_at": "2026-07-13T11:40:58", "published_display": "13 Jul 2026 11:40", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA flags Enlivex\u2019s Allocetra as potential new option for painful knee osteoarthritis", "summary": "The FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to Enlivex's Allocetra for age-related knee osteoarthritis in patients 64 and older, aiming to accelerate its development. This designation was based on positive Phase I/IIa trial data showing significa", "url": "https://www.stocktitan.net/news/ENLV/enlivex-receives-fda-regenerative-medicine-advanced-therapy-rmat-8tzm8f2vmzb5.html", "source_name": "Stock Titan", "published_at": "2026-07-13T11:40:58", "published_display": "13 Jul 2026 11:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exclusive: FDA grants RMAT designation to Enlivex\u2019s Allocetra for knee OA", "summary": "The FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to Enlivex's experimental immunotherapy Allocetra for age-related knee osteoarthritis in patients aged 64 and older. This designation is expected to provide the biotech company with enhanced access to t", "url": "https://ca.investing.com/news/stock-market-news/exclusive-fda-grants-rmat-designation-to-enlivexs-allocetra-for-knee-oa-4730690", "source_name": "Investing.com Canada", "published_at": "2026-07-13T10:40:58", "published_display": "13 Jul 2026 10:40", "sentiment": "positive", "sentiment_pct": 95, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tranche Update on Enlivex Therapeutics Ltd.'s Equity Buyback Plan announced on September 18, 2023.", "summary": "", "url": "https://news.google.com/rss/articles/CBMi_wFBVV95cUxOd2hRX0ZNUklMX2xTOWJDajBOeE1XRE9WcklsbTZGRFV3YWpmVnVWcHp2UFFJaEt4Qkp0QzNuQ0FyN3FfUXVmcmxGNDJWVS01NEE1Y2xiTzEtYl8xNHBZRThlREhLY2RrdVFhYTJ0Qng3VW5wWHA4Tk10NkdZWkt5SXI0MHVUeERZM25QR3hUc2FZMkEwWm1YTTNMSWpyVDMxUjlKZG1DcVBkSTBFWlFiQTBqWHFTS3BtZGpfRE5aVmlDdFk3THp4UUJDUDh6dmJBbzRvMklXWU8yd1gzc1VRdzgtX3JQdnFFVnF1UVFnY0RweFBvdEIyVEdpX1JVcXM?oc=5", "source_name": "marketscreener.com", "published_at": "2026-07-12T15:57:57+00:00", "published_display": "12 Jul 2026 15:57", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enlivex: Shareholders Board Members Managers and Company Profile | IL0011319527", "summary": "This article provides a comprehensive company profile for Enlivex Ltd. (IL0011319527), an Israel-based clinical-stage macrophage reprogramming immunotherapy company. It details the company's business description, key executives, board members, major shareholders, and financial ov", "url": "https://www.marketscreener.com/quote/stock/ENLIVEX-56422776/company/", "source_name": "www.marketscreener.com", "published_at": "2026-07-11T03:39:41", "published_display": "11 Jul 2026 03:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enlivex Sets 1-for-15 Reverse Stock Split Ahead of July 9 Nasdaq Debut", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7gFBVV95cUxOZUVPMmFMTWV3MUV3RFZvem5fYWxNOVdUNkZDbE94Y0prS3A5V3V1ekNOZ3FXU3N3SG9kUEFkRERIOGpldUhqN1JjVnJRNjVtLTlyZEktVWpOU25sRmFRTVZlZXhNVTdCQTJybWNfaFdzNVJ1MXVZUjNKMTAyZFYyUHB1Vl9VdEFENWdQeTUwM0lySGRNU1BkaktmdEx2ckJrYUpXRk9KMGlDV1dmY2dsQkZxeDNvT014enF1NHdNRGY5bVFPYXFwMDBfcTFRQnNyTXVvZUJoNnFFaEJqeFRRUHdUWVpjQ1g2SVluaW9R?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-07-08T07:00:00+00:00", "published_display": "08 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enlivex Announces 1-for-15 Reverse Stock Split Effective July 9, 2026", "summary": "Enlivex Ltd. announced a 1-for-15 reverse stock split of its ordinary shares, effective July 9, 2026. This action will combine every fifteen ordinary shares into one, reducing the total number of outstanding shares and proportionately adjusting par value, exercise prices, and the", "url": "https://www.manilatimes.net/2026/07/07/tmt-newswire/globenewswire/enlivex-announces-1-for-15-reverse-stock-split-effective-july-9-2026/2379846/amp", "source_name": "The Manila Times", "published_at": "2026-07-07T14:12:17", "published_display": "07 Jul 2026 14:12", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enlivex announces 1-for-15 reverse stock split effective Wednesday By Investing.com", "summary": "Enlivex Ltd. announced a 1-for-15 reverse stock split of its ordinary shares, effective Wednesday, July 9, 2026, to address its stock trading near a 52-week low. This adjustment will reduce the number of authorized shares and outstanding ordinary shares, but will not affect share", "url": "https://ng.investing.com/news/stock-market-news/enlivex-announces-1for15-reverse-stock-split-effective-wednesday-93CH-2588871", "source_name": "Investing.com Nigeria", "published_at": "2026-07-07T14:12:16", "published_display": "07 Jul 2026 14:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enlivex Therapeutics outlines its immunotherapy approach as a clinical-stage biotech", "summary": "Enlivex Therapeutics is a clinical-stage biotechnology company focused on developing immunotherapy candidates for severe inflammatory conditions and oncology, with shares traded on Nasdaq. The company's strategy involves modulating immune cell behavior to address unmet medical ne", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/enlivex-therapeutics-outlines-its-immunotherapy-approach-as-a/69714766", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T13:52:07", "published_display": "07 Jul 2026 13:52", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enlivex (ENLV) Implements Reverse Stock Split", "summary": "Enlivex Ltd (ENLV) announced a 1-for-15 reverse stock split effective July 9, 2026, a strategic move to increase its share price and comply with Nasdaq listing requirements. The biotechnology company, focused on developing Allocetra for osteoarthritis, has a P/E ratio of 0.1x, po", "url": "https://www.gurufocus.com/news/8947326/enlivex-enlv-implements-reverse-stock-split", "source_name": "GuruFocus", "published_at": "2026-07-07T13:42:07", "published_display": "07 Jul 2026 13:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enlivex to shrink share count 15-to-1 on July 9 as Nasdaq trading continues", "summary": "Enlivex (Nasdaq: ENLV) announced a 1-for-15 reverse stock split of its ordinary shares, effective July 9, 2026, to maintain Nasdaq listing compliance. This action will reduce the number of outstanding shares from 252,480,222 to approximately 16,832,015 and increase the par value ", "url": "https://www.stocktitan.net/news/ENLV/enlivex-announces-1-for-15-reverse-stock-split-effective-july-9-rfk94ihhvnlh.html", "source_name": "Stock Titan", "published_at": "2026-07-07T12:12:08", "published_display": "07 Jul 2026 12:12", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enlivex (Nasdaq: ENLV) enacts 1-for-15 reverse split and cuts share count", "summary": "Enlivex Ltd. (Nasdaq: ENLV) announced a 1-for-15 reverse stock split, effective July 9, 2026, to consolidate its ordinary shares. This action will reduce authorized shares from 2.375 billion to approximately 158.3 million and outstanding shares from 252.48 million to about 16.83 ", "url": "https://www.stocktitan.net/sec-filings/ENLV/6-k-enlivex-ltd-current-report-foreign-issuer-48a517248570.html", "source_name": "Stock Titan", "published_at": "2026-07-07T12:12:07", "published_display": "07 Jul 2026 12:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enlivex (NASDAQ: ENLV) highlights RAIN listing on Gate and $1.14B treasury", "summary": "Enlivex Ltd. (NASDAQ: ENLV) announced that its primary treasury asset, the RAIN token, is expected to be listed on the Gate cryptocurrency exchange on June 24, 2026, at 10:00 AM UTC. This listing aims to increase RAIN's accessibility, global reach, and liquidity, supporting Enliv", "url": "https://www.stocktitan.net/sec-filings/ENLV/6-k-enlivex-ltd-current-report-foreign-issuer-cf58f98a14ad.html", "source_name": "Stock Titan", "published_at": "2026-06-24T12:12:02", "published_display": "24 Jun 2026 12:12", "sentiment": "positive", "sentiment_pct": 64, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enlivex token gets Gate listing, widening access to its $1.14B treasury asset", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxOdHJtNHNHSDUtcTR5U2R4MUEtdEhEYTIzOXRYUDZPTEdWaXFQS2xDQzVRUHlFYmpuVGVQOVFpRm1LbmNBZlA5REVNVkZHVVU3NlJZSnRtOFowaG9CUlZfdzBpeEtKRkV6ZXpjUVozc25RX0V2Y1JWR056dm1TejdTSk9Ba29KcWNRM0hzWEZDNkxQNzFjVTJMdkI0YVNkU3lzR0YyZjJHMlUzNlZBbEZxSGlpT05VQXQ0bDQ3NDVHRQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enlivex Therapeutics Ltd (ENLV) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Enlivex Therapeutics Ltd (ENLV), detailing its current price momentum score, support and resistance levels, and insights from various technical indicators and moving averages. The analysis suggests that the stock is currently trading ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-enlv/technical", "source_name": "TradingKey", "published_at": "2026-06-23T11:10:14", "published_display": "23 Jun 2026 11:10", "sentiment": "negative", "sentiment_pct": 36, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 6K Enlivex Therapeutics Ltd For: 22 June By Investing.com", "summary": "This article reports on the filing of Form 6K by Enlivex Therapeutics Ltd for June 22nd. The filing is brief and includes the stock ticker ENLV, which experienced a slight decline. The page also features various financial market data and related news.", "url": "https://za.investing.com/news/stock-market-news/form-6k-enlivex-therapeutics-ltd-for-22-june-93CH-4337745", "source_name": "Investing.com South Africa", "published_at": "2026-06-23T08:10:26", "published_display": "23 Jun 2026 08:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enlivex Therapeutics Ltd (ENLV) Risk Assessment: Volatility, Financial Risk & Investment Risk", "summary": "This article provides a risk assessment for Enlivex Therapeutics Ltd (ENLV), noting that no specific risk assessment score is currently available, but the industry average is 3.36. It highlights the company's beta value of 1.67, indicating higher volatility compared to the S&P 50", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-enlv/risk-assesment", "source_name": "TradingKey", "published_at": "2026-06-23T05:40:54", "published_display": "23 Jun 2026 05:40", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enlivex Reports $1.14 Billion Value in RAIN Token Holdings as of June 20, 2026", "summary": "Enlivex Ltd. announced holdings of 79.5 billion RAIN tokens valued at $1.14 billion as of June 20, 2026, contributing to a Treasury NAV per Share of $4.67. The company employs a dual strategy, advancing its Allocetra\u2122 immunotherapy and managing a prediction markets treasury throu", "url": "https://www.quiverquant.com/news/Enlivex+Reports+%241.14+Billion+Value+in+RAIN+Token+Holdings+as+of+June+20%2C+2026", "source_name": "Quiver Quantitative", "published_at": "2026-06-22T12:50:00", "published_display": "22 Jun 2026 12:50", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[6-K] Enlivex Ltd. Current Report (Foreign Issuer) | ENLV SEC Filing - Form 6-K", "summary": "Enlivex Ltd. filed a Form 6-K report, updating on its digital asset treasury. As of June 20, 2026, the company held 79.57 billion RAIN tokens, valued at approximately $1.14 billion, leading to an unaudited Treasury NAV per Share of $4.67. Enlivex emphasizes its dual strategy of a", "url": "https://www.stocktitan.net/sec-filings/ENLV/6-k-enlivex-ltd-current-report-foreign-issuer-808f6becf666.html", "source_name": "Stock Titan", "published_at": "2026-06-22T12:39:44", "published_display": "22 Jun 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enlivex says its RAIN token treasury is worth about $1.14 billion", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQSm1mVDEtOUJVMWRXMGRQS25YT2FwTjdDaEowaFh1bUN1dWUtc094UnNVVVN6UXVIQWFaemtNYzV6UC1YWGVIR1JDVjdJSGFLLWQ4Wm94eHpmSzMtT3RQRmJ0eTdULVlGZkFCZ25SY2tFNWJjUkpRRmxnYU9wQ1k5YkdINzlENjNqNllMZGJFUVdKVkVfZEpITFNmNDRvaC10c2d0aTVJbzlIVmxMektqZUVB?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ENLV Stock - weekly outlook with no verified hook", "summary": "This article provides a weekly outlook for Enlivex Therapeutics (ENLV) stock, noting the absence of a live-verifiable corporate hook in recent search results. It focuses on the company's clinical-stage profile as a macrophage reprogramming immunotherapy business and highlights th", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/enlv-stock-weekly-outlook-with-no-verified-hook/69591420", "source_name": "AD HOC NEWS", "published_at": "2026-06-20T15:40:30", "published_display": "20 Jun 2026 15:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enlivex Therapeutics Ltd (ENLV) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Enlivex Therapeutics Ltd (ENLV) has an earnings forecast score of 8.00, placing it well within its industry. Analysts predict a price target of $7.00, with a consensus \"Buy\" rating based on one analyst's assessment. The company's previous EPS was -$0.09, with the next quarter's E", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-enlv/earnings", "source_name": "TradingKey", "published_at": "2026-06-19T02:19:54", "published_display": "19 Jun 2026 02:19", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enlivex Therapeutics Ltd (ENLV) Financial Health: Profitability & Balance Sheet Analysis", "summary": "This article provides an analysis of Enlivex Therapeutics Ltd's (ENLV) financial health, highlighting its weak financial status and low operating efficiency within the Biotechnology & Medical Research industry. The company's financial score is 5.38, ranking it poorly compared to ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-enlv/financial-health", "source_name": "TradingKey", "published_at": "2026-06-18T23:10:18", "published_display": "18 Jun 2026 23:10", "sentiment": "negative", "sentiment_pct": 31, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enlivex Therapeutics Ltd (ENLV) Institutional Confidence", "summary": "This article provides an \"Institutional Confidence\" overview for Enlivex Therapeutics Ltd (ENLV), indicating a score of 3.00, unchanged from the previous score as of June 18, 2026. It highlights institutional shareholding data, specifically mentioning Shai A. Novik's stake of 858", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-enlv/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T06:19:54", "published_display": "18 Jun 2026 06:19", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enlivex Therapeutics Ltd (ENLV) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article from TradingKey provides an overview of Enlivex Therapeutics Ltd (ENLV), focusing on its revenue breakdown. However, it indicates that relevant data regarding business segments, regional revenue, and profit contribution for ENLV have not yet been disclosed by the com", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-enlv/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T21:40:25", "published_display": "17 Jun 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enlivex Therapeutics Ltd (ENLV) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Enlivex Therapeutics Ltd (ENLV) stock information, focusing on its dividend and stock split history. It indicates that the company has not distributed any dividends in the past five years and has no record of stock splits. The page also displa", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-enlv/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T21:40:25", "published_display": "17 Jun 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enlivex Therapeutics Ltd (ENLV) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of Enlivex Therapeutics Ltd (ENLV), listing major shareholders such as Gems Foundation, Token Factory, and Sobrinia Ltd, along with their respective proportions. It also presents a breakdown of shareholder types, indicating that corp", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-enlv/ownership", "source_name": "TradingKey", "published_at": "2026-06-17T20:40:25", "published_display": "17 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enlivex receives Australian patent for osteoarthritis treatment", "summary": "Enlivex Ltd. has been granted an Australian patent for its Allocetra therapy to treat osteoarthritis, providing intellectual property protection in Australia through at least 2040. This news comes as the company's shares trade near their 52-week low, and they are currently conduc", "url": "https://au.investing.com/news/stock-market-news/enlivex-receives-australian-patent-for-osteoarthritis-treatment-93CH-4487321", "source_name": "Investing.com Australia", "published_at": "2026-06-16T06:39:19", "published_display": "16 Jun 2026 06:39", "sentiment": "positive", "sentiment_pct": 69, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enlivex receives Australian patent for osteoarthritis treatment By Investing.com", "summary": "Enlivex Ltd. has been granted an Australian patent for its Allocetra therapy for osteoarthritis, extending intellectual property protection until at least 2040. This news comes as the company's shares trade near a 52-week low, despite positive clinical trial data for Allocetra in", "url": "https://uk.investing.com/news/stock-market-news/enlivex-receives-australian-patent-for-osteoarthritis-treatment-93CH-4728114", "source_name": "Investing.com UK", "published_at": "2026-06-15T17:39:25", "published_display": "15 Jun 2026 17:39", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enlivex Therapeutics Granted Patent in Australia for Allocetra to Treat Osteoarthritis", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/enlivex-therapeutics-granted-patent-australia-133827958.html", "source_name": "MT Newswires", "published_at": "2026-06-15T13:38:27+00:00", "published_display": "15 Jun 2026 13:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Australian patent backs Enlivex cell therapy for knee osteoarthritis to 2040", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQRnZhZ2RIdDN3N3VPUHhSYVpTWW0tTkJ6QzY1b25DX0VYNXJFZ25Ra25FNk55LU5fX1dkaHBWaWoyaEx2QVphbFIzWm02Q0ZtMC03SWFDNFFqeHgxZkhVcENYOFZlejl1TmxLU1RFODF3R3ZWQ2dSMFhwNmxJLXVkcjFHaEpza3ROZ0Zuemp5RjBRdWgtdFMzZjFSOEdibzlNNlBvTWg0ZHktN1NCNXNkZE5VVHZ6MlhzR1dHMGdGTQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enlivex Therapeutics stock (IL0011283620): Data monitoring, Nasdaq notice and next steps for investo", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxNaWlhdFNRRktUYWpmdDh0N0YwSUxsQ3BHQ1JoTElybFV5VkZwUWEzaE9hVFA1b0F0T2hvM2tGUnVybk1LbmRlVzQ3enFIbThreEpSYk1ScEppM3F0bUZJc3JDMnNqMXRHWVhDazFzWVRLVVhlU1l2czlmdHZlVWotYm1PN2JITXM1ZHVCTktKY3NsX285UUxDdW1ielZqOUstMjFsX2lZRUN6Y29EUlUtQl9uLWgtcEltZXE4OFBiSV9lQldISzJV?oc=5", "source_name": "ad-hoc-news.de", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enlivex brings longevity\u2011prediction markets pitch to $18T Paris summit", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxNR0kzcEs0TWcybndNUmtmajFvMVd6MkJlbVY2b3hBQUo0N0oxb2pyUVFpNVplYVNhaG9nR3FGMkpFZ0g1bGU1WVNiZWlNZFlocERRaHI2VU1OTlJIakc1b29PWV91aUZTMlhEcXkwTkFTTFZSSnVzdThvN0M3OVh6SXFMSUt1NFo0V2oxenQ2NldQRFFtN2lycno4Wldvdm0xZnpURWdmM2ExaVd4MkpMTkFuLW5UZ2ZzMmZB?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enlivex advances Allocetra while expanding into prediction markets", "summary": "", "url": "https://finance.yahoo.com/video/enlivex-advances-allocetra-while-expanding-173935308.html", "source_name": "Proactive", "published_at": "2026-05-11T17:39:35+00:00", "published_display": "11 May 2026 17:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enlivex to Present Phase IIa 3-month and 6-month Data of Allocetra at OARSI 2026 World Congress", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/enlivex-present-phase-iia-3-123000346.html", "source_name": "GlobeNewswire", "published_at": "2026-04-23T12:30:00+00:00", "published_display": "23 Apr 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "New knee osteoarthritis data from Enlivex heads to OARSI 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxOamw5aldETWpMOVVDN05TZkE3bHFkREJVd3RWLVctR0tIYlNqeHlYZTZUV1VXaDNWQ19GanhXYUQzc0dBXzZtSDVfZ2FZOWcwZHJUOW8tWTAxVTdkNGpzdDlMcFBxU1NDRW9ZSUJFMDN0MzdYZFl6NXg2VzJzX3NkYV9qSDY1czlfVXZDZWszN09qakM5R1hWZFkzQWxrcmtaUG1RR2VUcFVkbGUtaGw1cFM2MlNCaDdCUldldkF3aw?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-23T07:00:00+00:00", "published_display": "23 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright Highlight Improved Balance Sheet Supporting Enlivex Ltd. (ENLV) Outlook", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxQajhpWE9vUFFRVGcyQUQwOGdrU0ZzUFFzNFpYSFFZTmdGR1U2c1lIQU93MF92STlYZExGdDBLWFVReERlV21BTWpkVlg0Ymd6Q1NTajlGSUpBQnpnVGJfUDlYczVLUnl2aF9CZTBJRzd4Zkg3Vk9KWXQ3WHBXWjFBVU51dV8ycHVSUjV4WHgxWE8zVjNoMmxaZGNEN2RPVHQ2Q3pOWQ?oc=5", "source_name": "Market source", "published_at": "2026-04-20T07:00:00+00:00", "published_display": "20 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enlivex Ltd. Reports $1.23 Billion Net Income for 2025 Driven by Treasury Asset Appreciation | ENLV Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxPeGJTWmJhQXptdDhuLV84V1g0QmZuckJxREgwQ0RXR1V5X2pxMDBsQUF4bDV2dTJxaXdfeW4yR1BsdEd3WnljTi1QWGpLSTlnRWljMldmVnE2REJEN0ZSVVVoSVVvcDQ5R0NjN25IWXd5dTdDSUNJUDFPVF9JRWF1RVJBNGhLcmRjU3N0R0tlWDVUWUI4ZldJZnhqNWctNV9VUHJzUFltMXp2VC1NVURXYkJuNkhHMlVLaEhJc1B1U0RheXNOOXc?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Backed by $21M debt, Enlivex buys 3B more RAIN tokens at discount", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxPS1MydUlJQkllRDctV3p3NW1iTzZfOHl4RWNyNVY2dEdnekNldzJYMEFaRUc5MkxHMllCRHhvXy1qY1NIMVloWFJ6R1ZJMTJrUG9tSnNaa1BHNC1DN0N1ZTByS3V4ZllwZTBKX2ttNFh1dl9QTjFsekp0VFhMeFFiOEo4UG81LUlSMmk1TEx4T3F1MmNKVFU0Z1dXOEtFTmRhOW1VMzMwQ0M4a0R4NTI1dnRUd05aMmxFTmpJeDFBQWM?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-24T07:00:00+00:00", "published_display": "24 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enlivex Rebrands as Enlivex Ltd. Following Shareholder Approval", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2gFBVV95cUxQNEdkcHlRS3NPUXl6MlU1MFhsRE43MFRzZWpQTHc2eTRqUE9rZHNEQzBCWnNHWXI2cWdUWGlnanRZV0pJVkJOSXdQbkxLZWlxdm1MUlFlck5wOEZ6NHVMdFJHYmhaYTdPUkUxTUFXNUx5U20wek1RVnFPMjJwM2JYdlJ2ZGNLTGZNWFZDREhERDBYOVVqUVBWRUphQWRQVnEyTzU5NkRJSnhvTUJhdGIyOXdEN3Qzbm53VjRFZFVSZXB3WHl0U2ZKSmlOdHhOTkgzSV9MV2dPeDdmUQ?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enlivex Unveils $212M Rain Token DAT Strategy as RAIN Surges Over 120%", "summary": "", "url": "https://news.google.com/rss/articles/CBMigwFBVV95cUxOUmhHX0sxbEFSZ1ZHWlMxaGZ4Q0VOLXFINUM0Zm1qbFk5R0hvVEdFNXdVNkZNVFc5ZURtSXppVXR3V2dkY2d2dTlya3MtRDZaWktSS3R0ZkpPd2RVUHlZWTY2MF9VSEhsdlB4azFUaUE1Y2ZKYWRrcnFSdmFMYXpCSXJzYw?oc=5", "source_name": "Market source", "published_at": "2025-11-24T08:00:00+00:00", "published_display": "24 Nov 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EXCLUSIVE: Enlivex Raises Over $200 Million To Launch First Public Company Prediction Markets Play", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxOX0lnVUcwZzEwOVVQOFZzT3pxbzRiWXFXRUVqWlJRZjA2TDVKd19XTGtMNGVWOGJEWVVhREU3SGMzbzRoRWw2cFN6QzRCb3k1dkNBLWdaeU9rQzhfR3FaTnpRV2ZSa2lIbG01ZUhxaVJwUDRTSlp4bkdTdHF6LVFSNHNaSTB4dw?oc=5", "source_name": "Market source", "published_at": "2025-11-24T08:00:00+00:00", "published_display": "24 Nov 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why We're Watching Enlivex Therapeutics' (NASDAQ:ENLV) Cash Burn Situation", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7AFBVV95cUxNdGlMejQxeVY4RXA0NTlObHNGVTFfZ0RGUHFMOVU5STM0UEFxdjFiTFh4WC1DQnYwa2c0eGlfU3VDX3RNUWp4NlNZd2E4bUFLa2JBU0c4WGZibGJYWXJtUFRuVW15VXJ4bzN6N3N2a28xQVozaTRyUUJSVml6TWlHN2dPUWEtS19udHdybGNfYWdLZFF3VklMSmxrYnN2aDdkc1JPREJWMkt4anFnc1l5ZE9HX25IZzNYemJXMlROelJCUXFWTkhZQ0xFMGRMQ3BLbFVvTDRnVjExUThPYWVDVE5ZaXBnbm1yd1JsSdIB8gFBVV95cUxPR01lQ2ZTMUI3T2J6a1NsZTVkT19JSERpeXdvRi1tT2puSEJkVnZtczdGaEpfYzBBcFFZMEVmTExUdDlySEo3S3lJSWFGa0gySlBmOUY4Vkd0dDRQWEVxOFRsTWt3UnVmclROMEs2MEVtQU9EOUVMcWNmcmttYWRjTWN5UC1xaGRGY1U0RkgzdVNwbXMzMk50U015cWp2OTFpZlFta1FoVjY2MXJVWnFVY2dKZUJROVVodnpJV3BHQnpsa2VpMEpIbDFJVHFpS0Q1UlpKWXczWGxFdXliNUtDcHV2ZUtNc0hUU2gtSGh1bmlxdw?oc=5", "source_name": "simplywall.st", "published_at": "2025-10-07T07:00:00+00:00", "published_display": "07 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enlivex Therapeutics (ENLV) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE5vNHo5VGxxS01hR0NtWExILUtLSHVUay1oaDZPQUxfTXI0by14b1BkNGxlUWV5U1lpbk1PTVhzcGtwZDltNjhuakI3d3ByZXkwbmtOQTdoS3QwUQ?oc=5", "source_name": "MarketBeat", "published_at": "2020-01-10T08:42:01+00:00", "published_display": "10 Jan 2020 08:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOWWM3V1pmZzdlY1llRTljQmNLQ2UwdDdQaFVEcng2WVdrNE9qNzRrNVpBVlJNMGltQUhBUG1qellCVHNiM09fUkFHRW1kMEpvazJoLU11N3c4YnlWUXpmVl82aWNKeTA4U1RwSHNNSVd4d0lwWHRJclQ2TGNHWUpBQTgzbTBMVk05VGxYN0RwcmpTYklOQUFSWDhsSHZlQVpndmlPRGNvTmRmeHNILWg4ZE5jMjRoN01XNENiaVU2UDUyOWJfYUZCTm5URmtwTHJsTjJYNHo3RkxsQjBSMnBmdVZVWkFwN2PSAewBQVVfeXFMT3htM016bEt0TTdyOXE2amppMGpubTNfOFU4cGpxd2dFZkJDTjR3c0ZqOHpHYWZoamNLdmkxVmNYNklxTEM4NTU0bDZwUTZ1SW5Jc1c4NmRJN3lKQUVqUUNYYWptd2ZYNE9TeEhMRzFvbEt0bjk1TVhyVG44UnJnNDllTlFsalJVUTZwcEEzWXljbzdaQXdWWDlHQW56bGxqeG90UlFmaFFLekJlUlNIOVE4SGNHcE9pOW1KSllleVdwNERiaVl2NmxtNTNyaUtnSFY1VHUzcDJsWE9xb3R1ajZ2RGhkXzJzTldMOVA?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 94, "total_relevant": 58, "sentiment_summary": {"positive": 16, "negative": 6, "neutral": 36, "score": 55, "total": 58, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 83, "events": [{"event": "general", "label": "Market update", "weight": 19.8, "count": 36}, {"event": "earnings", "label": "Earnings", "weight": 5.91, "count": 13}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.65, "count": 3}, {"event": "capital_return", "label": "Capital return", "weight": 1.1, "count": 2}, {"event": "analyst", "label": "Analyst action", "weight": 0.55, "count": 1}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}], "positive_events": 16, "negative_events": 6}, "market_context": {"has_market_context": true, "latest_close": 6.86, "latest_week": "2026-07-10", "one_week_move": -13.3, "four_week_move": -31.8, "twelve_week_move": -46.8, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -1.329674, "market_dynamics_buy_signal": false, "relative_strength": -60.456315, "fair_value_gap": -68.6, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 39.5272, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-13.3% over one week, -31.8% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 65, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 12}, {"label": "Market source", "count": 11}, {"label": "TradingKey", "count": 8}, {"label": "simplywall.st", "count": 3}, {"label": "The Manila Times", "count": 2}, {"label": "GuruFocus", "count": 2}, {"label": "MT Newswires", "count": 2}, {"label": "The Globe and Mail", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 49}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 36}, {"label": "Earnings", "count": 13}, {"label": "Balance sheet", "count": 3}, {"label": "Capital return", "count": 2}, {"label": "Analyst action", "count": 1}, {"label": "Deals and strategy", "count": 1}, {"label": "Guidance", "count": 1}, {"label": "Regulatory and legal", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "55/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "83/100 classification confidence."}, {"label": "Company focus", "value": "49", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-13.3% over one week, -31.8% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Enlivex Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Allocetra\u2122 in Age-Related Knee Osteoarthritis"}], "updated_at": "2026-07-17T21:03:50.929341+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}